Citigroup’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Citigroup’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-104,107	Closed	-$3.79M	–	7496
2016 Q4	$3.79M	Buy	+104,107	New	+$3.68M	﹤0.01%	2158
2016 Q2	–	Sell	-14	Closed	–	–	7740
2016 Q1	$0	Buy	+14	New	+$87	﹤0.01%	8042
2015 Q3	–	Sell	-106	Closed	-$1K	–	8078
2015 Q2	$1K	Buy	+106	New	+$910	﹤0.01%	7426

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Citigroup's CLCD Position: Q1 2017 in Review

Citigroup sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 104,107 shares — an estimated $3.79M sold.

Citigroup first reported a position in CLCD in Q2 2015 and held it in 3 quarters. The position peaked at $3.79M in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

Citigroup reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Citigroup sold 104,107 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $3.79M.
Citigroup first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 3 quarters.
Citigroup's CoLucid Pharmaceuticals, Inc. position peaked at $3.79M in Q4 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on Citigroup's 13F filing for Q1 2017, filed 12 May 2017.